Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued on Monday. The firm set a “sell” rating on the biotechnology company’s stock.

Other equities research analysts also recently issued reports about the company. JMP Securities restated a “market outperform” rating and set a $6.00 price target on shares of Cellectis in a research note on Friday, May 31st. Oppenheimer lowered their price target on Cellectis from $11.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, June 12th.

Cellectis Price Performance

CLLS opened at $2.40 on Monday. The stock has a 50-day moving average price of $2.11 and a 200-day moving average price of $2.46. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.92 and a quick ratio of 1.92. The firm has a market cap of $133.39 million, a PE ratio of -1.86 and a beta of 3.10. Cellectis has a 1 year low of $0.96 and a 1 year high of $3.77.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.05. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. The company had revenue of $9.50 million during the quarter, compared to the consensus estimate of $6.00 million. Sell-side analysts predict that Cellectis will post -0.54 earnings per share for the current fiscal year.

Institutional Trading of Cellectis

Several hedge funds have recently modified their holdings of the company. Long Focus Capital Management LLC raised its holdings in shares of Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Cellectis during the 2nd quarter valued at approximately $29,000. Principal Financial Group Inc. increased its position in shares of Cellectis by 2.9% during the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares during the last quarter. Finally, Baillie Gifford & Co. increased its position in shares of Cellectis by 1.3% during the 1st quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock valued at $2,192,000 after purchasing an additional 10,605 shares during the last quarter. 63.90% of the stock is owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.